TEVA

Teva Pharmaceutical has entered a definitive agreement to acquire Emalex Biosciences, a private company whose lead asset, ecopipam, is a first-in-class therapy for Tourette syndrome in children. Phase 3 data showed statistically significant results on the primary efficacy endpoint, with an NDA submission expected in the second half of 2026. The deal adds a near-regulatory-stage neuroscience asset to Teva's pipeline as part of its stated pivot-to-growth strategy.